SEATTLE, July 1, 2026
Sana Biotechnology, Inc. announced that new clinical data from a first-in-human investigator-sponsored study evaluating UP421, its allogeneic primary islet cell therapy engineered with the company’s proprietary Hypoimmune Platform (HIP) technology, will be presented during a symposium at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026, taking place September 28 to October 2, 2026, in Milan, Italy. The presentation will focus on the transplantation of UP421 into a patient with type 1 diabetes without the use of immunosuppression, highlighting the potential of engineered hypoimmune islet cells to achieve durable transplantation while avoiding the long-term risks associated with immune-suppressing medications. The announcement reflects continued clinical progress in Sana’s mission to develop next-generation engineered cell therapies for chronic diseases.
Symposium to Highlight First-in-Human Clinical Findings
The clinical data will be presented during the symposium titled “Stem cell-derived islets in clinical trials: towards a cure for type 1 diabetes,” with Sana’s presentation, “Hypoimmune islets: engineering immune evasion for durable transplantation without immunosuppression,” scheduled for October 2, 2026, at the EASD Annual Meeting. The presentation will showcase findings from an investigator-sponsored first-in-human clinical study evaluating UP421, providing insights into the feasibility of transplanting engineered allogeneic islet cells without conventional immunosuppressive therapy. The study represents an important milestone in the clinical development of immune-evasive cell therapies designed to overcome one of the major limitations of current cell transplantation approaches for patients with type 1 diabetes.
Hypoimmune Platform Designed to Eliminate Immunosuppression
UP421 incorporates Sana’s proprietary Hypoimmune Platform (HIP) technology, which is designed to engineer transplanted cells capable of evading immune detection while maintaining therapeutic function. By enabling immune evasion, the platform aims to eliminate the need for lifelong immunosuppressive drugs, which are commonly required following conventional cell or organ transplantation and are associated with significant long-term safety risks. In type 1 diabetes, destruction of insulin-producing beta cells requires lifelong insulin replacement, making durable islet cell transplantation an attractive therapeutic strategy. If successful, hypoimmune-engineered cell therapies could significantly expand access to regenerative treatments while improving patient safety and long-term outcomes.
Advertisement
Clinical Development Expands Engineered Cell Therapy Pipeline
The upcoming EASD 2026 presentation underscores Sana Biotechnology’s continued advancement of its engineered cell therapy platform across multiple therapeutic areas. The company is focused on developing innovative approaches that repair or replace damaged cells while overcoming immune rejection through advanced gene engineering technologies. Presentation of first-in-human clinical data at one of the world’s leading diabetes conferences highlights the growing clinical maturity of Sana’s regenerative medicine platform and its potential to transform the treatment of type 1 diabetes. As development progresses, UP421 and the Hypoimmune Platform may represent a significant step toward durable, broadly accessible cell therapies capable of restoring insulin production without the burden of chronic immunosuppression.
Source: Sana Biotechnology press release
